Skandinaviska Enskilda Banken Ab (Publ) Protagonist Therapeutics, Inc Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $20.3 Billion
- Q1 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 18,914 shares of PTGX stock, worth $655,370. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,914
Previous 18,914
-0.0%
Holding current value
$655,370
Previous $433,000
26.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PTGX
# of Institutions
187Shares Held
59.5MCall Options Held
35.7KPut Options Held
72.3K-
Farallon Capital Management LLC San Francisco, CA5.74MShares$199 Million0.77% of portfolio
-
Black Rock Inc. New York, NY5.57MShares$193 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.32MShares$184 Million2.47% of portfolio
-
Bvf Inc San Francisco, CA3.76MShares$130 Million3.25% of portfolio
-
State Street Corp Boston, MA3.27MShares$113 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.7B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...